A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Brief description of study

This is a Phase 1, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in combination with AB122 (programmed cell death-1 inhibitor) and standard chemotherapy (nab-paclitaxel [NP] and gemcitabine [Gem]) in participants with advanced pancreatic cancer.


Clinical Study Identifier: s19-01021
ClinicalTrials.gov Identifier: NCT04104672


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.